US 2013/0296416 A1Published application

Selective inhibition of beta1- adrenergic receptors for the treatment of pediatric heart failure

AssigneeThe Regents of the University of Colorado, a body corporate

InventorsBrian Stauffer, Carmen Sucharov, Shelley Miyamoto

Life of this patent

Estimating the term…

Abstract

Provided are methods of treating heart failure in children using B1-selective adrenergic receptor antagonists, alone or in combination with other agents, including B-2-selective adrenergic receptor agonists.

Claims14

Dependent claims

A method of treating heart failure in a pediatric subject comprising administering to said subject an effective amount of a β1-adrenergic receptor-selective antagonist.

Dependencies are inferred from the claim text.

Facts

Application: 13/817,969Filed 25 Aug 2011
Priority: 26 Aug 2010
Published: 7 Nov 2013
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 31/137
Having aromatic rings , e.g. ketamine, nortriptyline: arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
A61K 31/138
Having aromatic rings , e.g. ketamine, nortriptyline: aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/165
Amides, e.g. hydroxamic acids: having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/35
Having oxygen as the only ring hetero atom, e.g. fungichromin: having six-membered rings with one oxygen as the only ring hetero atom

Family

Application61/377,277Us provisional application · filed 26 Aug 2010
US 9,456,997 B2Related patent
US 2013/0296416 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results